OCULAR THERAPEUTIX, INC annual report, FY2020

Ocular Therapeutix, Inc. — FY 2020 Form 10-K

Reporting period: Fiscal year ended December 31, 2020. This summary covers the full year; the filing does not provide a standalone Q4 income statement. Ocular Therapeutix is an ophthalmology-focused biopharmaceutical company. Its marketed products are DEXTENZA, for post-surgical ocular inflammation and pain, and ReSure Sealant, for corneal incision closure. Its pipeline includes four clinical-stage programs and a preclinical Regeneron collaboration.

Financial performance and position

Metric	FY 2020	FY 2019
Product revenue	$17.4 million	$4.2 million
Cost of product revenue	$2.1 million	$2.3 million
Research and development	$28.7 million	$41.1 million
Selling and marketing	$26.6 million	$24.5 million
General and administrative	$22.9 million	$22.1 million
Loss from operations	$(62.8) million	$(85.8) million
Net loss	$(155.6) million	$(86.4) million
Net loss per share, basic and diluted	$(2.56)	$(1.91)
Cash used in operating activities	$(53.6) million	$(77.6) million

• Revenue rose about 312%, primarily as DEXTENZA commercialization expanded. 2020 product revenue included $15.7 million from DEXTENZA and $1.7 million from ReSure; 2019 included $2.2 million and $2.0 million, respectively. Product gross margin was approximately 88% in 2020, based on reported product revenue less cost of product revenue.
• Operating expenses declined $9.8 million, mainly because of lower R&D personnel and other costs following the 2019 restructuring; direct R&D spending on programs increased. Selling and marketing costs rose as the DEXTENZA launch continued.
• Net loss widened largely because of an $86.2 million noncash loss from remeasuring the convertible-note derivative liability, versus a $4.3 million gain in 2019. The derivative liability was $98.3 million at year-end and is sensitive to stock price and other model assumptions.
• Cash and cash equivalents were $228.1 million at year-end; current assets were $246.2 million and current liabilities $26.7 million. The company reported $53.6 million of operating cash burn and $228.0 million of financing cash inflow, including approximately $210.0 million net proceeds from three 2020 public offerings.
• Debt included a $25.0 million credit facility and $37.5 million principal of 2026 convertible notes, plus $4.2 million accrued interest. The credit facility bears interest at LIBOR subject to a 2% floor plus 7.25% (9.25% at year-end); monthly principal payments began in January 2021. The notes accrue 6% interest and have an initial conversion price of $6.50 per share.
• Management estimated year-end cash would fund planned operating costs, debt service and capital spending through 2023, subject to assumptions about DEXTENZA sales, COVID-19, expenses and development pace. The financial statements also state funding sufficiency through at least the next 12 months; both are management estimates, not assurance.

Material changes and business developments

• DEXTENZA revenue grew substantially from its 2019 launch, but COVID-19 disruptions to elective ophthalmic procedures affected commercialization. Three specialty distributors accounted for 42%, 29% and 12% of 2020 revenue, indicating significant customer concentration.
• Gross-to-net provisions on DEXTENZA sales increased to 22.2% of gross sales in 2020 from 16.3% in 2019, primarily reflecting a new purchase-volume rebate program.
• The company received a $12 million upfront payment from AffaMed for Asian-market rights to DEXTENZA and OTX-TIC. It recorded the amount as deferred revenue at year-end and had recognized no revenue under the agreement because no product had yet been delivered.
• Regeneron collaboration work shifted in 2020 to preclinical development of an extended-delivery aflibercept formulation for suprachoroidal delivery. Regeneron’s option had not been exercised by year-end.
• At December 31, 2020, 76.0 million common shares were outstanding, up from 50.3 million a year earlier, reflecting equity issuance and other share activity. March 1, 2021 shares outstanding were 76.1 million.

Outlook, commentary and key risks

• The FDA accepted DEXTENZA’s supplemental application for allergic-conjunctivitis itching and set an October 18, 2021 target action date. If approved, management expected a U.S. launch in the first half of 2022.
• Management planned to expand the DEXTENZA sales force in 2021. It expected R&D spending to increase as trials advanced, including Phase 2 work for OTX-TIC and continued OTX-CSI development; topline OTX-CSI data were anticipated in Q4 2021 and OTX-DED data in the first half of 2022.
• DEXTENZA’s Medicare transitional pass-through status was scheduled to end in July 2022. If it lapses, separate reimbursement could be lost, potentially harming sales to ambulatory surgery centers and hospital outpatient departments. A Category I procedure code was scheduled to take effect January 1, 2022.
• The company has incurred substantial losses, expects continued losses, and may need additional capital despite its cash runway estimate. Future equity financing could dilute shareholders; debt and collaboration financing may restrict operations or require rights to be shared.
• COVID-19 could continue to reduce elective procedures, impede sales and patient recruitment, and disrupt clinical trials or supplies. The filing describes prior trial enrollment delays and delayed entry of site data for OTX-TKI, underscoring operational and data-quality risks.
• Manufacturing and regulatory risks include a February 2021 FDA Form 4003 request for records on DEXTENZA manufacturing and quality systems; the review was ongoing, with a possible onsite inspection. The company also disclosed prior FDA inspection observations and CRLs relating to manufacturing deficiencies.
• Other material risks include competition and generic alternatives, reimbursement uncertainty, reliance on a sole-source PEG supplier and lack of long-term raw-material supply agreements, intellectual-property challenges, clinical-trial failure, and potential dilution or cash obligations under convertible notes.

Investor verification priorities

• Verify subsequent DEXTENZA revenue, in-market unit trends, gross-to-net deductions, distributor inventories and customer concentration.
• Track the FDA’s October 2021 action on the allergic-conjunctivitis sNDA and the status of the manufacturing Form 4003 review or any inspection findings.
• Assess whether the stated cash runway through 2023 remains credible against operating cash burn, commercial growth, clinical spending and scheduled credit-facility amortization.
• Review the convertible-note derivative valuation and potential dilution or settlement exposure; the $86.2 million 2020 fair-value loss was noncash, but the $98.3 million year-end liability is model-sensitive.
• Confirm the timing and results of pipeline trials, progress under the AffaMed and Regeneron agreements, and any milestone or reimbursement cash actually received.
• Monitor the July 2022 pass-through reimbursement transition, the effectiveness of the new procedure code, and whether payer coverage supports DEXTENZA adoption.